Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection.
Cytokines are increasingly used for the therapy of infections in patient populations with special defects in immunity (chemotherapy, bone marrow transplantation, chronic granulomatous disease). The recognition of multiple defects in the systems of the interferon-gamma (IFN-gamma) receptor, interleukin-12 (IL-12) receptor and IL-12 p40 emphasizes the critical roles that cytokines play in preventing and clearing infection. The cases of patients with partially responsive IFN-gamma receptors (autosomal dominant and partial defects) are ideal candidates for successful cytokine prophylaxis and therapy. Better understanding of the critical elements of the cytokine pathways may show us ways to circumvent these defects with complementary cytokine cascades.
Holland
S M
SM
Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, 11N103, 10 Center Dr., MSC 1886, Bethesda, MD 20892-1886, USA. smh@nih.gov
D016207:Cytokines / Q000172:deficiency / Q000235:genetics / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D006801:Humans; D018664:Interleukin-12 / Q000172:deficiency / Q000235:genetics; D009164:Mycobacterium Infections / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D017471:Receptors, Interferon / Q000172:deficiency / Q000235:genetics; D018123:Receptors, Interleukin / Q000172:deficiency / Q000235:genetics
D016207:Cytokines; D017471:Receptors, Interferon; D018123:Receptors, Interleukin; D018664:Interleukin-12